Tamiflu, Vioxx Pediatric Adverse Event Reports To Be Presented At Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pediatric Advisory Committee will also hear pediatric adverse event reports on Agrylin, Paraplatin, Diflucan, Camptosar, Ferrlecit and Imitrex at Nov. 18 meeting.
You may also be interested in...
Roche Increases Tamiflu Manufacturing Capacity In Time For 2006 Season
President Bush will request $7.1 bil. for pandemic avian flu preparedness, $1 bil. of which will be earmarked for antiviral stockpiling.
Shire/Noven Methypatch For ADHD To Be Reviewed By Psychopharm Committee
Companies seek indication for once-daily methylphenidate patch for the treatment of attention deficit/hyperactivity disorder in children ages six to 12 years.
J&J Concerta, Methylphenidate Adverse Events Not New Signal, Committee Says
FDA's pediatric committee is hesitant to recommend a labeling change for attention deficit/hyperactivity disorder drugs based on current data. FDA should, however, communicate concerns about psychiatric events to the public, possibly through Drug Watch website.